Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;42(5):483-493.
doi: 10.1016/j.clinre.2018.03.003. Epub 2018 Mar 31.

Individuals affected by eosinophilic gastrointestinal disorders have complex unmet needs and frequently experience unique barriers to care

Affiliations

Individuals affected by eosinophilic gastrointestinal disorders have complex unmet needs and frequently experience unique barriers to care

Girish Hiremath et al. Clin Res Hepatol Gastroenterol. 2018 Oct.

Abstract

Introduction: Eosinophilic gastrointestinal disorders (EGIDs) are a rare but emerging healthcare problem. Patient advocacy groups (PAGs) have an important role in representing the EGID community, and serve as valuable research partners. By leveraging the partnership between medical researchers and PAGs, we examined the unmet needs and barriers to care perceived by individuals affected by EGIDs. Next, we examined if these varied between adult EGID patients and adult caregivers of children with EGID.

Methods: Adult EGID patients and adult caregivers of children (<18 years) with EGIDs participated in this study. PAGs conducted focus groups comprised of individuals affected by EGIDs to identify domains and questions meaningful to the EGID community and this information was used to develop an online REDCap survey. The survey consisted of 58 questions across medical, healthcare, social, and emotional impact domains. It was distributed via the PAGs' web-based platforms. Demographic data, and responses to questions on a six-point Likert scale were collected and analyzed.

Results: Of the 361 responses analyzed, 90 (25%) were from adult EGID patients and 271 (75%) were from adult caregivers. Of the applicable responses, in the medical domain only 19% of participants indicated that repeated endoscopies to monitor response to treatment was convenient. In the healthcare domain, 67% indicated that lack of insurance coverage for elemental formula was a barrier. In the social domain, only 5% of respondents reported adequate awareness of EGIDs in schools. In the emotional domain, 64% had experienced significant stress due to EGID related out-of-pocket costs. Multivariate logistic regression revealed that some of these responses varied between adult EGID patients and adult caregivers of children with EGID. The respondents indicated highest priority for improvement in the medical domain compared to other domains.

Conclusions: Individuals affected by EGIDs have a constellation of complex unmet needs and perceived barriers across medical, healthcare, social and emotional domains. Addressing unmet needs in the medical domain is relatively more important for the EGID community. Understanding unmet needs and barriers will likely help design improved patient-centered EGID care paradigms.

Keywords: Eosinophilic esophagitis; Eosinophilic gastritis; Eosinophilic gastroenteritis; Eosinophilic gastrointestinal disorders; Health promotion; Health services research; Healthcare barriers; Rare diseases; Survey; Unmet needs.

PubMed Disclaimer

Conflict of interest statement

Competing interests

GSH: The author declares no competing interest

EK: The author declares no competing interest

MJS: The author declares no competing interest

MS: The author declares no competing interest

WB: The author declares no competing interest

CR: The author declares no competing interest

SK: The author declares no competing interest

DM: The author declares no competing interest

KS: The author declares no competing interest

PA: The author declares no competing interest

JS: The author declares no competing interest

SKG: The author declares no competing interest

GTF: No potential conflicts of interest related to this paper. Consultant for Banner and Shire.

MER: No potential conflicts of interest related to this paper. Consultant for NKT Therapeutics, Pulm One, Spoon Guru, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, Allakos, and Novartis and has an equity interest in the first three listed and Immune Pharmaceuticals, and royalties from reslizumab (Teva Pharmaceuticals). M.E.R. is an inventor of patents, owned by Cincinnati Children’s.

ESD: No potential conflicts of interest related to this paper. Consultant for Adare, Alivio, Alkalso, Banner, Celgene/Receptos, Enumeral, GSK, Regeneron, Shire. Research funding from Adaire, Meritage, Miraca, Nutricia, Celegene/Receptos, Regeneron, Shire.

Figures

Figure 1
Figure 1
Schematic representation of the study protocol
Figure 2
Figure 2
Radar plot illustrating priority for improvement assigned to each domain by the participants

Comment in

References

    1. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID)*. Journal of Allergy and Clinical Immunology. 2004;113:11–28. - PubMed
    1. Jensen ET, Martin CF, Kappelman MD, Dellon ES. Prevalence of Eosinophilic Gastritis, Gastroenteritis, and Colitis: Estimates From a National Administrative Database. Journal of Pediatric Gastroenterology and Nutrition. 2016;62:36–42. - PMC - PubMed
    1. Dellon ES, Jensen ET, Martin CF, Shaheen NJ, Kappelman MD. Prevalence of eosinophilic esophagitis in the United States. Clin. Gastroenterol. Hepatol. 2014;12:589–96. e1. - PMC - PubMed
    1. Fahey LM, Liacouras CA. Eosinophilic Gastrointestinal Disorders. Pediatr. Clin. North Am. 2017;64:475–85. - PubMed
    1. Cheng K, Gupta SK, Kantor S, Kuhl J, Aceves S, Bonis P, et al. Translational Science of Rare Diseases. IOS Press; Creating a multicenter rare disease consortium – the consortium of eosinophilic gastrointestinal disease researchers (CEGIR) pp. 1–15. Preprint. - PMC - PubMed

Publication types

Supplementary concepts